Based in Austria, Cutanos is a startup.
Cutanos develops a targeted immune therapy platform using a ligand-based delivery system to direct mRNA and protein antigens specifically to Langerhans cells via minimally invasive skin administration to enhance vaccine efficacy and reduce side effects.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.